MX2012013372A - Metodos para tratar infecciones bacterianas recurrentes. - Google Patents

Metodos para tratar infecciones bacterianas recurrentes.

Info

Publication number
MX2012013372A
MX2012013372A MX2012013372A MX2012013372A MX2012013372A MX 2012013372 A MX2012013372 A MX 2012013372A MX 2012013372 A MX2012013372 A MX 2012013372A MX 2012013372 A MX2012013372 A MX 2012013372A MX 2012013372 A MX2012013372 A MX 2012013372A
Authority
MX
Mexico
Prior art keywords
methods
bacterial infection
treating
recurring bacterial
treating recurring
Prior art date
Application number
MX2012013372A
Other languages
English (en)
Inventor
Youe-Kong Shue
Pamela Sears
Sherwood Gorbach
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012013372(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Publication of MX2012013372A publication Critical patent/MX2012013372A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Métodos para tratar infecciones gastrointestinales (GI) recurrentes de Clostridium difficile en un sujeto, que comprenden administrarle al sujeto una cantidad eficaz de un compuesto de la presente invención.
MX2012013372A 2010-05-18 2011-05-18 Metodos para tratar infecciones bacterianas recurrentes. MX2012013372A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34592310P 2010-05-18 2010-05-18
PCT/US2011/037006 WO2011146624A2 (en) 2010-05-18 2011-05-18 Methods of treating recurring bacterial infection

Publications (1)

Publication Number Publication Date
MX2012013372A true MX2012013372A (es) 2013-05-01

Family

ID=44992320

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013372A MX2012013372A (es) 2010-05-18 2011-05-18 Metodos para tratar infecciones bacterianas recurrentes.

Country Status (9)

Country Link
US (1) US20140315838A1 (es)
AU (1) AU2011255633B2 (es)
BR (1) BR112012029262A8 (es)
CA (1) CA2799531A1 (es)
CL (1) CL2012003202A1 (es)
CO (1) CO6670519A2 (es)
MX (1) MX2012013372A (es)
PE (1) PE20130308A1 (es)
WO (1) WO2011146624A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579354B2 (en) * 2012-01-23 2017-02-28 Santalis Pharmaceuticals, Inc. Sandalwood oil and its uses related to clostridium infections
US20150157653A1 (en) * 2012-03-16 2015-06-11 Optimer Pharmaceuticals, Inc. Prevention of Clostridium Difficile Infection in High Risk Patients
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins

Also Published As

Publication number Publication date
WO2011146624A2 (en) 2011-11-24
AU2011255633A1 (en) 2013-01-10
BR112012029262A8 (pt) 2018-06-12
CA2799531A1 (en) 2011-11-24
BR112012029262A2 (pt) 2017-07-11
US20140315838A1 (en) 2014-10-23
WO2011146624A9 (en) 2012-05-10
CL2012003202A1 (es) 2013-07-12
CO6670519A2 (es) 2013-05-15
AU2011255633B2 (en) 2014-09-11
PE20130308A1 (es) 2013-04-06

Similar Documents

Publication Publication Date Title
SG10201804809RA (en) Clostridium difficile antibodies
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
MX2011007930A (es) Conjugados de insulina cristalina.
AU2018256482A1 (en) Antibodies Against Clostridium Difficile
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
GB2518813A (en) OMV vaccine against Burkholderia infections
PH12014501032A1 (en) 2-thiopyrimidinones
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
GB2482817A (en) Novel use
SG10201900541QA (en) Derivatives of xanthone compounds
IN2014DN03298A (es)
MX2012013372A (es) Metodos para tratar infecciones bacterianas recurrentes.
MX2012002299A (es) Uso de cetoenoles ciclicos contra bacterias fitopatogenas.
MX2012013374A (es) Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos.
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
MX349944B (es) Lactobacillus brevis productor de reuterina.
MX2013005759A (es) Metodos para detectar bajo grado de inflamacion.
UA117672C2 (uk) Антибактеріальні сполуки
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
IN2015DN00962A (es)
WO2011097027A3 (en) Methods for treating or inhibiting infection by clostridium difficile
MX2012012509A (es) Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.
GB201114923D0 (en) Immunogenic proteins and compositions
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERCK SHARP & DOHME CORP.*

HC Change of company name or juridical status

Owner name: MERCK SHARP & DOHME CORP.*

FA Abandonment or withdrawal